Q2/H1 results published recently by the Biopharmaceutical Corporation focused on the biology of healing, reflected intensified development activity, as its small molecule program hits the clinic on multiple indications and enrolment on its biotherapeutic candidates accelerates. R&D was up to C$35.8m from C$20.4m in H1. This was mitigated by a certain extent by an increase in revenues with net losses up to C$42.6m from C$34m. We leave our full year numbers unchanged. Following a successful
22 Aug 2016
Strong financial and clinical position to execute
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong financial and clinical position to execute
ProMetic Life Sciences (PLI:TSE) | 0 0 1.3% | Mkt Cap: 1,075m
- Published:
22 Aug 2016 -
Author:
Derren Nathan -
Pages:
8
Q2/H1 results published recently by the Biopharmaceutical Corporation focused on the biology of healing, reflected intensified development activity, as its small molecule program hits the clinic on multiple indications and enrolment on its biotherapeutic candidates accelerates. R&D was up to C$35.8m from C$20.4m in H1. This was mitigated by a certain extent by an increase in revenues with net losses up to C$42.6m from C$34m. We leave our full year numbers unchanged. Following a successful